Evidence map›Paper›PMID 33631857›Full record

ArticleInternal medicine journal2021

Managing COVID-19 in patients with inflammatory bowel disease: navigating unprecedented challenges.

Ralley E Prentice, Aysha Al-Ani, Britt Christensen

Open access · bronzeAbstract read
In one paragraph

Article in Internal medicine journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Severe COVID-19: Drugs and Clinical Trials.Journal of clinical medicine · 2023
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ralley E PrenticeDepartment of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID 0000-0002-4331-9295
Aysha Al-AniDepartment of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID 0000-0002-4735-5234
Britt ChristensenDepartment of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID 0000-0002-8746-4275
The Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has demanded a rapid adaptation in healthcare provision, including patients with inflammatory bowel disease (IBD). This viewpoint discusses some of the unique challenges in managing comorbid IBD and COVID-10 experienced by our team at The Royal Melbourne Hospital, which was at the epicentre of the COVID-19 'second-wave' surge in Melbourne.

Indexed as

Delivery of Health CareAustraliaCOVID-19HumansInflammatory Bowel DiseasesPandemicsCOVID-19immunosuppressioninflammatory bowel disease

Identifiers

PMID33631857
PMCPMC8013000
OpenAlexW3132186282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.